Unique ID issued by UMIN | UMIN000037986 |
---|---|
Receipt number | R000043292 |
Scientific Title | Effect on concentration (and cognitive function) by single ingestion of a test food |
Date of disclosure of the study information | 2019/09/17 |
Last modified on | 2019/12/27 09:45:49 |
Effect on concentration (and cognitive function) by single ingestion of a test food
Effect on concentration (and cognitive function) by single ingestion of a test food
Effect on concentration (and cognitive function) by single ingestion of a test food
Effect on concentration (and cognitive function) by single ingestion of a test food
Japan |
Healthy subjects
Adult |
Others
NO
The purpose of this study is to examine the influence on concentration by single intake of test food for healthy Japanese men aged 30 years or older and younger than 60 years.
Efficacy
Cognitrax
VAS questionnaire,POMS2 shorter version,Uchida Kraepelin test
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
On the day intake of the test food
Wash out
On the day intake of the placebo
On the day intake of the placebo
Wash out
On the day intake of the test food
30 | years-old | <= |
60 | years-old | > |
Male
1. Japanese male aged 30 years or older and younger than 60 years at the time of the informed consent.
2. Non smoker
3. Subject who has understood the purpose of the study, and agreed to participate it by signing the written informed consent.
1. Subject who is taking medication or under medical treatment because of some serious illness.
2.Subject who is under exercise therapy or dietetic therapy.
3. Subject who has an allergy for test food.
4. Subject who has or had a history of either medicine or alcohol dependence syndrome.
5. Subject who has or had a history of mental illness (depression) or sleep disturbance.
6. Subject who is on a night-shift or is a shift worker.
7. Subject whose lifestyle is extremely irregular.
8. Subject who has an unbalanced diet.
9. Subject who is disease or history such severe diseases such as brain disease, malignant tumor, immune disease, diabetes, liver disease (hepatitis), kidney disease, heart disease, thyroid disease, adrenal disease, other metabolic diseases person.
10. Subject who uses health foods ,supplements and medicines that affect concentration (theanine, caffeine, polyphenols, soy lecithin, DHA / EPA, taurine, Ginkgo biloba etc.)
11. Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
12. Subject who has blood drawn 200mL within the past 1 months or 400mL within the past 3 months from the day of the consent acquisition.
13. Subject who can't keep the daily records.
14.Subject who is considered as an inappropriate candidate by the doctor in charge.
90
1st name | Daisuke |
Middle name | |
Last name | Ochitani |
HUMA R&D CORP
Clinical Development Division
108-0014
Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
03-3431-1260
ochitani@huma-rd.co.jp
1st name | Daisuke |
Middle name | |
Last name | Ochitani |
HUMA R&D CORP
Clinical Development Division
108-0014
Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
03-3431-1260
ochitani@huma-rd.co.jp
HUMA R&D CORP
Asahi Quality and Innovations Co., Ltd.
Profit organization
Ethics Committees of Nihonbashi Egawa Clinic
2F Kotobuki Build. 1-1-3 Yaesu Chuo-ku, Tokyo 103-0028 Japan
03-5204-0311
jim@medipharma.co.jp
NO
2019 | Year | 09 | Month | 17 | Day |
Unpublished
89
Completed
2019 | Year | 07 | Month | 03 | Day |
2019 | Year | 07 | Month | 16 | Day |
2019 | Year | 08 | Month | 07 | Day |
2019 | Year | 10 | Month | 18 | Day |
2019 | Year | 10 | Month | 24 | Day |
2019 | Year | 10 | Month | 28 | Day |
2019 | Year | 12 | Month | 26 | Day |
2019 | Year | 09 | Month | 11 | Day |
2019 | Year | 12 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043292